<

UCB (EBR:UCB) UCB Media Room: UCB announces changes on Board of Directors

Transparency directive : regulatory news

15/01/2021 07:02
https://mb.cision.com/Public/18595/3268152/ba9218ae57934300_800x800ar.jpg ** UCB announces changes on Board of Directors ------------------------------------------------------------ Brussels (Belgium), January 15, 2021 =E2=80=93 7:00 AM (CET)=C2=A0 UCB today announces the cooptation of Professor Susan Gasser as new member = of UCB's Board of Directors effective as of 1 January 2021. Prof Gasser rep= laces Professor Alice Dautry who reached the statutory age limit early 2020= and kindly accepted to stay with the Board of UCB until her successor coul= d replace her. The cooptation of Prof Susan Gasser was conducted in accorda= nce with both the statutory rules of UCB and the BCCA (Belgian Code of Comp= anies and Associations). Prof Susan Gasser qualifies as independent Board m= ember and she is also appointed as a member of the Scientific Committee of = the Board in replacement of Prof Alice Dautry. The ratification of Susan Ga= sser=E2=80=99s cooptation and her appointment for a full mandate of 4 years= will be proposed at the next Annual General Meeting in April 2021.=C2=A0 Mrs Evelyn du Monceau, UCB=E2=80=99s Chair of the Board said: =E2=80=9CUCB= =E2=80=99s Board of Directors and Executive Committee want to express their= sincere thanks to Alice Dautry for the pivotal role she has played over th= e past 5 years. Her role on UCB=E2=80=99s Scientific Committee, deep expert= ise in cell biology, immunology, receptors and infectious diseases coupled = with her dedication has greatly helped the company on its transformation an= d growth journey.=E2=80=9D=C2=A0 Mr Jean-Christophe Tellier, CEO of UCB said: =E2=80=9CI=E2=80=99m delighted= to welcome Susan Gasser who brings a wealth of experience in various field= s including biophysics, molecular biology and genetics =E2=80=93 key to UCB= =E2=80=99s future development. Her roles on renowned scientific review pane= ls and international advisory roles make her the perfect candidate to help = guide the company for the coming years.=E2=80=9D Prof Susan Gasser is a professor at the University of Basel and holds guest= professorships at the University of Lausanne and the Tokyo Institute of Te= chnology. She was the Director of the Friedrich Miescher Institute for Biom= edical Research (FMI) from 2004 to 2019, and continued as an FMI research g= roup leader until the end of 2020. On February 1, 2021, she becomes Directo= r of the ISREC Foundation, based in Lausanne, which is dedicated to transla= tional cancer research. =C2=A0Professor Gasser studied at the University of= Chicago and completed her PhD at the University of Basel in the field of b= iochemistry. She was a professor of Molecular Biology at the University of = Geneva from 2001 =E2=80=93 2004. She has authored more than 250 primary art= icles and reviews and received numerous awards for her work. A full biograp= hy can be found on UCB=E2=80=99s corporate website (https://www.ucb.com/inv= estors/UCB-Governance) . UCB=E2=80=99s 2021 Annual General Meeting will be held on April 29, 2021. For further information =C2=A0=C2=A0 =C2=A0 Corporate Communications Laurent Schots=C2=A0 Media Relations, UCB =C2=A0 T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0 Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 7 500 people op= erating in ~ 40 countries, the company generated revenue of =E2=82=AC 4.9 b= illion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us= on Twitter: @UCB_news Forward looking statements =E2=80=93 UCB This press release contains forward-looking statements including, without l= imitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =E2= =80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=E2= =80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestimate= s=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccontinu= e=E2=80=9D and similar expressions. These forward-looking statements are ba= sed on current plans, estimates and beliefs of management. All statements, = other than statements of historical facts, are statements that could be dee= med forward-looking statements, including estimates of revenues, operating = margins, capital expenditures, cash, other financial information, expected = legal, arbitration, political, regulatory or clinical results or practices = and other such estimates and results. By their nature, such forward-looking= statements are not guarantees of future performance and are subject to kno= wn and unknown risks, uncertainties and assumptions which might cause the a= ctual results, financial condition, performance or achievements of UCB, or = industry results, to differ materially from those that may be expressed or = implied by such forward-looking statements contained in this press release.= Important factors that could result in such differences include: changes i= n general economic, business and competitive conditions, the inability to o= btain necessary regulatory approvals or to obtain them on acceptable terms = or within expected timing, costs associated with research and development, = changes in the prospects for products in the pipeline or under development = by UCB, effects of future judicial decisions or governmental investigations= , safety, quality, data integrity or manufacturing issues; potential or act= ual data security and data privacy breaches, or disruptions of our informat= ion technology systems, product liability claims, challenges to patent prot= ection for products or product candidates, competition from other products = including biosimilars, changes in laws or regulations, exchange rate fluctu= ations, changes or uncertainties in tax laws or the administration of such = laws, and hiring and retention of its employees. There is no guarantee that= new product candidates will be discovered or identified in the pipeline, o= r that new indications for existing products will be developed and approved= . Movement from concept to commercial product is uncertain; preclinical res= ults do not guarantee safety and efficacy of product candidates in humans. = So far, the complexity of the human body cannot be reproduced in computer m= odels, cell culture systems or animal=C2=A0models. The length of the timing= to complete clinical trials and to get regulatory approval for product mar= keting has varied in the past and UCB expects similar unpredictability goin= g forward. Products or potential products which are the subject of partners= hips, joint ventures or licensing collaborations may be subject to disputes= between the partners or may prove to be not as safe, effective or commerci= ally successful as UCB may have believed at the start of such partnership. = UCB=E2=80=99 efforts to acquire other products or companies and to integrat= e the operations of such acquired companies may not be as successful as UCB= may have believed at the moment of acquisition. Also, UCB or others could = discover safety, side effects or manufacturing problems with its products a= nd/or devices after they are marketed. The discovery of significant problem= s with a product similar to one of UCB=E2=80=99s products that implicate an= entire class of products may have a material adverse effect on sales of th= e entire class of affected products. Moreover, sales may be impacted by int= ernational and domestic trends toward managed care and health care cost con= tainment, including pricing pressure, political and public scrutiny, custom= er and prescriber patterns or practices, and the reimbursement policies imp= osed by third-party payers as well as legislation affecting biopharmaceutic= al pricing and reimbursement activities and outcomes. Finally, a breakdown,= cyberattack or information security breach could compromise the confidenti= ality, integrity and availability of UCB=E2=80=99s data and systems.=C2=A0 Given these uncertainties, you should not place undue reliance on any of su= ch forward-looking statements. There can be no guarantee that the investiga= tional or approved products described in this press release will be submitt= ed or approved for sale or for any additional indications or labelling in a= ny market, or at any particular time, nor can there be any guarantee that s= uch products will be or will continue to be commercially successful in the = future. UCB is providing this information, including forward-looking statements, on= ly as of the date of this press release and expressly disclaims any duty to= update any information contained in this press release, either to confirm = the actual results or to report or reflect any change in its forward-lookin= g statements with regard thereto or any change in events, conditions or cir= cumstances on which any such statement is based, unless such statement is r= equired pursuant to applicable laws and regulations.=C2=A0 Additionally, information contained in this document shall not constitute a= n offer to sell or the solicitation of an offer to buy any securities, nor = shall there be any offer, solicitation or sale of securities in any jurisdi= ction in which such offer, solicitation or sale would be unlawful prior to = the registration or qualification under the securities laws of such jurisdi= ction. GenericFile UCB Changes on Board of Directors Jan 15 2021 ENG (https://mb.cision.com/Pu= blic/18595/3268152/9dd6592a1bee8281.pdf)=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x58364x1x6868579x24000= x6&Email=3Dregnews%40symexglobal.com.=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=


Other stories

28/03/2024 18:00
28/03/2024 12:25
28/03/2024 16:55
28/03/2024 20:47
28/03/2024 13:03
28/03/2024 20:53
28/03/2024 20:53
28/03/2024 13:13
27/03/2024 23:52
28/03/2024 20:14
28/03/2024 16:34
28/03/2024 17:33
28/03/2024 18:38
28/03/2024 09:33
28/03/2024 19:49
28/03/2024 20:23
28/03/2024 20:51
28/03/2024 09:59
28/03/2024 10:49
27/03/2024 15:52
28/03/2024 14:28
28/03/2024 13:31
28/03/2024 18:47
28/03/2024 19:00
28/03/2024 17:15
28/03/2024 13:11
28/03/2024 18:00
28/03/2024 19:13
28/03/2024 13:59
28/03/2024 14:14
27/03/2024 21:46
28/03/2024 17:55
27/03/2024 13:40
28/03/2024 17:23
28/03/2024 13:25
28/03/2024 12:57
28/03/2024 16:44
28/03/2024 02:42